Company Overview
| Stock Name | Wuxi Bio |
|---|---|
| Stock Code | 02269 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 全球领先的生物制剂服务供应商,向制药及生物技术公司提供全面、综合及高度定制的生物制剂发现、开发及生产服务。 |
| Listing Date | 2017-06-13 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國上海市外高橋自貿區富特中路288號 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | wuxibiologics.com.cn |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 20.60 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | 192,982,500 shares |
| HK Public Offer Shares (Initial) | 19,298,500 shares (10.0%) |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | 173,684,000 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 1,134,118,057 shares |
| Greenshoe (Over-allotment Option) | No |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | No cornerstone investors |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 3,975,439,500 |
Stock Connect Inclusion Analysis
| Avg Daily HK Mkt Cap | HK$ 168.03B |
|---|---|
| Analysis Result | Already included in Stock Connect (both) |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | 盈利约人民币141.1百万元 |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2014 | 2015 | 2016 |
|---|---|---|---|
| Revenue | 331,850 | 557,042 | 989,029 |
| Cost of sales | -208,596 | -376,321 | -599,919 |
| Gross profit | 123,254 | 180,721 | 389,110 |
| Other income and gains, net | 12,753 | 6,917 | 7,523 |
| Selling and distribution expenses | -4,303 | -13,447 | -15,326 |
| Administrative expenses | -43,862 | -72,220 | -94,606 |
| Operating profit | 51,568 | 67,933 | 200,001 |
| Net finance costs | -2,556 | -2,531 | -24,155 |
| Profit before tax | 49,012 | 65,402 | 175,846 |
| Income tax expense | -7,034 | -20,893 | -34,750 |
| Profit for the year | 41,978 | 44,509 | 141,096 |
Balance Sheet
| Item | 2014 | 2015 | 2016 |
|---|---|---|---|
| Cash and cash equivalents | 5,948 | 158,229 | 169,102 |
| Trade and bills receivables | 160,398 | 283,275 | 419,376 |
| Inventories | 33,555 | 49,919 | 78,988 |
| Total current assets | 229,157 | 601,112 | 829,856 |
| Total assets | 636,670 | 1,356,716 | 1,984,996 |
| Total current liabilities | 260,894 | 1,201,928 | 800,825 |
| Total liabilities | 264,840 | 1,210,715 | 1,714,529 |
| Total equity | 371,830 | 146,001 | 270,467 |
| Interest-bearing borrowings | 55,410 | 455,859 | 1,129,443 |
Cash Flow Statement
| Item | 2014 | 2015 | 2016 |
|---|---|---|---|
| Net cash from operating activities | 21,505 | 107,150 | 81,921 |
| Net cash from investing activities | -50,120 | -336,216 | -421,144 |
| Net cash from financing activities | 30,436 | 377,400 | 332,763 |
| Net increase in cash | 1,772 | 152,281 | 10,873 |
| Depreciation of PP&E | 42,309 | 57,006 | 93,185 |
| Purchase of PP&E | -51,044 | -334,362 | -428,883 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 28.25 |
|---|---|
| First Day Open | HK$ 25.0 |
| First Day Change | 37.14% |
| First Day Volume | 143609000.0 |
| First Day Turnover | 3805510000.0 |
| Use of Proceeds | 1、約45.1%或1,428.3百萬港元,將用于償還我們全部未清償銀行融資;
2、約44.9%或1,420.3百萬港元,將用于建造新設施及設施改進及維護;
3、約10%或316.5百萬港元,將用于我們的營運資金及其他一般企業用途。 |
Underwriting Syndicate
Joint Sponsors (3)
Overall Coordinators (3)
Joint Bookrunners (3)
Joint Lead Managers (4)
Cornerstone Investors
This stock has no cornerstone investors.
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 李革 | — |
| Company Secretary | 黃躍;岑影文 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 控股股东为李革博士、赵博士、张朝晖先生、刘晓钟先生(一致行动),合计持股约80.59%;Biologics Holdings直接持股约75.43%。 |
|---|




